Supplementary Data from p53 Pathway Inactivation Drives &lt;i&gt;SMARCB1&lt;/i&gt;-deficient &lt;i&gt;p53&lt;/i&gt;-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition